Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Shawn Donahue who wrote (8480)	9/3/2003 8:49:56 AM
From: John Carragher	Read Replies (1) \| Respond to of 9523

according to ameritrade someone went from hold to strong buy. PFIZER INC (PFE): average recommendation changed from 1.63 to 1.54 (Moderate Buy). Recommendation Details: Stock Date Mean #Rec Str Buy Mod Buy Hold Mod Sell Str Sell PFE 09/03/03 1.54 24 18 1 4 0 1 PFE 09/02/03 1.63 24 17 1 5 0 1

To: Shawn Donahue who wrote (8480)	2/24/2005 10:40:27 AM
From: Shawn Donahue	Respond to of 9523

Pfizer to buy Idun Pharmaceuticals Thu Feb 24, 2005 08:55 AM ET CHICAGO, Feb 24 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research) said on Thursday it has agreed to buy private biotechnology company Idun Pharmaceuticals Inc. for an undisclosed sum.The San Diego, California-based company is focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases. Idun's lead compound, IDN-6556, is in midstage clinical trials in liver transplantation and in patients infected with Hepatitis C virus.Idun also is exploring potential treatments for inflammation and cancer. The acquisition is expected to close during the second quarter. yahoo.reuters.com